洛神花、綠藻及苦瓜在細胞及動物實驗中抑制脂肪堆積效果之探討

Investigation of the inhibitory effects of roselle, chlorella and bitter melon on lipid accumulation in vivo and in vitro study

黎氏錦秀(ThiCamTu Le)

指導教授 ： 吳亮宜

中原大學/工學院/生物科技研究所/碩士(2012年)

https://doi.org/10.6840/cycu201200931

摘要

摘要
在全世界，因為肥胖的發生率飛快的增加，造成了代謝症候群、糖尿病以及心血管等疾病的患病率顯著的上升，因此如何降低血中脂肪以改善及預防血脂異常、糖尿病以及高血壓等病徵的發生已成為研究上的重要課題。本實驗的目的在於評估多種不同食材組成的保健食品餵飼高果糖飼料誘發之代謝症候群大鼠後，對其血脂降低的能力及探討可能影響機制，以及在小鼠 FL83B 肝臟細胞株對棕櫚酸誘發之脂肪堆積產生之影響。
本實驗分為動物實驗以及細胞實驗兩大部分。動物實驗部分，先將 Sprague-Dawlay (SD) 大鼠隨機分成3組：餵飼一般商業飼料的空白組 (B) 組；餵飼 60% 高果糖飼料之控制組 (C) 組及餵飼 60%高果糖飼料與 0.5% 洛神花萃出物、0.4% 綠藻及 0.1% 苦瓜萃出物混合之實驗組 (T) 組。實驗共進行 10 週。實驗結束後測定代謝症候群之相關危險因子包含如血壓、體脂肪、血糖、血漿中三酸甘油酯 (TG) 以及血漿中總膽固醇含量 (TC) 之變化。
數據顯示，在眾多代謝症候群相關風險因子之中，餵飼高果糖飼料的 C 組與 B 組相較，在腹部脂肪、血壓以及血糖、血脂的部分有較高的現象。此一結果顯示食用高果糖飼料之大鼠會造成代謝症候群之發生。進一步評估高果糖飼料誘發血脂異常現象的機制，我們發現可能為乙醯輔酶A羧化酶蛋白磷酸化降低所致。而與 C 組相比較，T 組在收縮壓、禁食血糖以及肝臟脂肪含量的部分則是有顯著改善的現象。其中在肝臟脂肪含量下降的部分，造成此一結果的原因可能是因為肝臟中腺苷單磷酸活化蛋白激酶以及乙醯輔酶A羧化酶的磷酸化增加所導致。
在本實驗細胞實驗之部分則對利用棕櫚酸 (OA group) 誘發 FL83B 肝臟細胞株脂肪堆積後，探討本實驗所用保健食品洛神花、綠藻及苦瓜降低脂肪堆積的能力與機制。
II
在給予肝臟細胞株棕櫚酸處理 (OA 組) 後會誘發出顯著的脂肪堆積現象，而此現象會因為給予細胞洛神花、綠藻以及苦瓜而被抑制。而在西方墨點分析結果則顯示 此三種食材有略微增加腺苷單磷酸活化蛋白激酶以及乙醯輔酶A羧化酶磷酸化之現象發生，但與 OA 組相比較則沒有顯著差異。
根據研究結果，我們認為由洛神花、綠藻以及苦瓜三種食材所組成的複方保健食品似乎有改善肥胖及血脂異常的能力。

關鍵字

血脂異常 ； 乙醯輔酶A羧化酶 ； 代謝症候群 ； 腺苷單磷酸活化蛋白激酶

並列摘要

ABSTRACT
The worldwide rapidly growing prevalence of obesity has resulted in a significant increase in the metabolic syndrome (MS), diabetes mellitus and associated cardiovascular disease. Lipid-lowering therapies have been investigated to improve and prevent pathophysiologic conditions such as dyslipidemia, diabetes, and hypertension. Therefore, this study aims to evaluate the benefits from using the supplementation of various healthy foods on mechanism of lipid-lowering activity in high fructose diet-induced metabolic syndrome rats and in mice liver cell line (FL83B) under oleic acid condition.
This study was carried out into two parts. Firstly, male Sprague- Dawlay (SD) rats were be randomly divided into 3 groups: blank group (B): fed with normal diet; control group (C): fed with high fructose diet alone; treatment group (T): fed with high fructose diet plus 0.5% roselle, 0.4% chlorella and 0.1% bitter melon extract. The study lasted for 10 weeks. Risk factors of MS including blood pressure, body fat mass, plasma glucose, triglycerides (TG) and total cholesterol (TC) were measured at the end of 10 weeks dietary manipulation.
The data demonstrated that metabolic disorders such as higher abdominal fat mass, blood pressure, blood glucose and plasma lipid levels were shown in group C compared to group B. These results indicated that high fructose diet could cause a cluster of disorders in MS. In order to further evaluated the possible mechanism of high fructose diet associated with dyslipedimia, we found that the rats in group C showed a decrease phosphorylation activity of acetyl CoA carboxylase (ACC) protein.
Compared to group C, the significant improvement of systolic blood pressure, fasting plasma glucose and liver lipid contents were shown in group T. And the decrease of lipid profile in liver might result from the increased phosphorylation of AMP-activated protein kinase (AMPK) and ACC.
Moreover, this study also investigated the possible mechanism of lipid-lowering activity of healthy food in a oleic acid (OA) induced lipid accumulation model in FL83B hepatocyte cells. Protein content of AMPK, p- AMPK and ACC, p-ACC were measured by Western blot.
Treatment with oleic acid induced a significant lipid accumulation in hepatocyte cells which is suppressed by supplementation with roselle, chlorella and bitter melon respectively . In western blot assay showed these three healthy food slightly increased phosphorylation activity of AMPK and ACC but without difference with OA treatment group.
According to presents findings, we suggested that supplementation of combination of combination of roselle, chlorella, and bitter melon seems to be a good measure to obesity and improve dyslipidemia.

並列關鍵字

dyslipidemia ； MS ； ACC ； AMPK

參考文獻

Alberti, K.H., Zimmet, P.Z. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.

Araya, J., Rodrigo, R., Videla, L.A., Thielemann, L., Orellana, M., Pettinelli, P., Poniachik, J. 2004. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106: 138-144. Basciano, H., Federico, L., Adeli, K. 2005. Review: Fructose, insulin resistance, and metabolic dyslipidemia. Nutri Metab 2 (1): 5.

Brent A. Neuschwander-Tetri and Stephen H. Caldwell. 2003. Nolalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37: 1202-1219.

Bryne, C.D., and Wild, S.H. 2005. The metabolic syndrome. P 4-11.

Buhl, E. S., Jessen, N., Pold, R., Ledet, T., Flyvbjerg, A., Pedersen, S. B., Pedersen, O., Schmitz, O., and Lund, S. 2002. Long-Term AICAR Administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome. Diabetes 51: 2199-2206.